Caption Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-40,000
Closed -$274K 1137
2023
Q1
$274K Hold
40,000
0.01% 887
2022
Q4
$317K Buy
+40,000
New +$308K ﹤0.01% 991
2021
Q3
Sell
-30,000
Closed -$414K 1535
2021
Q2
$414K Buy
+30,000
New +$425K 0.01% 1087
2020
Q3
Sell
-30,000
Closed -$536K 1055
2020
Q2
$536K Sell
30,000
-2,500
-8% -$42.3K 0.02% 653
2020
Q1
$528K Sell
32,500
-246,200
-88% -$4.55M 0.03% 533
2019
Q4
$5.02M Buy
278,700
+131,800
+90% +$2.43M 0.17% 163
2019
Q3
$2.98M Buy
+146,900
New +$2.94M 0.15% 176

Other funds holding CHRS

Caption Management's CHRS Position: Q3 2021 in Review

Caption Management sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 12,000 shares — an estimated $167K sold.

Caption Management first reported a position in CHRS in Q2 2019 and held it in 2 quarters. The position peaked at $1.1M in Q2 2019. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • Caption Management reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
  • Caption Management sold 12,000 Coherus Oncology shares in Q3 2021, an estimated $167K.
  • Caption Management first reported a position in Coherus Oncology in Q2 2019 and held it in 2 quarters.
  • Caption Management's Coherus Oncology position peaked at $1.1M in Q2 2019.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Caption Management's 13F filing for Q3 2021, filed 12 Nov 2021.